Online inquiry

IVTScrip™ mRNA-Anti-EGFR, ABBV-221(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ915MR)

This product GTTS-WQ915MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Chimeric; Humanized
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, ABBV-221(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ915MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ2747MR IVTScrip™ mRNA-Anti-TNFSF11, AMG162(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AMG162
GTTS-WQ5778MR IVTScrip™ mRNA-Anti-EGFR, cetuximab-IR700(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA cetuximab-IR700
GTTS-WQ8537MR IVTScrip™ mRNA-Anti-CD4, Hu5A8(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA Hu5A8
GTTS-WQ3808MR IVTScrip™ mRNA-Anti-NCAM1, BB-10901(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BB-10901
GTTS-WQ10507MR IVTScrip™ mRNA-Anti-APP, LY3002813(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LY3002813
GTTS-WQ10713MR IVTScrip™ mRNA-Anti-ALB&IL17A, M-1095(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA M-1095
GTTS-WQ4597MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-986015
GTTS-WQ1726MR IVTScrip™ mRNA-Anti-CD40, ADC-1013(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ADC-1013
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW